Sudan Loganathan
Stock Analyst at Stephens & Co.
(3.64)
# 844
Out of 5,182 analysts
48
Total ratings
53.66%
Success rate
6.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATNM Actinium Pharmaceuticals | Reiterates: Overweight | $5 | $1.09 | +358.72% | 3 | Mar 31, 2026 | |
| IMNM Immunome | Maintains: Overweight | $33 → $30 | $21.48 | +39.66% | 4 | Mar 4, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $95 → $100 | $85.27 | +17.27% | 4 | Mar 2, 2026 | |
| APGE Apogee Therapeutics | Initiates: Overweight | $95 | $84.01 | +13.08% | 1 | Dec 17, 2025 | |
| CADL Candel Therapeutics | Reiterates: Overweight | $15 | $5.02 | +198.80% | 2 | Dec 8, 2025 | |
| PYXS Pyxis Oncology | Maintains: Overweight | $5 → $8 | $1.45 | +451.72% | 2 | Nov 24, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $14 → $15 | $11.22 | +33.69% | 3 | Nov 10, 2025 | |
| DCTH Delcath Systems | Maintains: Overweight | $25 → $18 | $9.70 | +85.57% | 4 | Nov 5, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $35 | $39.67 | -11.77% | 1 | Oct 28, 2025 | |
| CCCC C4 Therapeutics | Reiterates: Overweight | $6 | $2.84 | +111.27% | 3 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $32.34 | +39.15% | 3 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $15.79 | +89.99% | 4 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $29 → $60 | $43.98 | +36.43% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $33 | $24.98 | +32.11% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $3.67 | +117.98% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $15 | $4.89 | +206.75% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $33.38 | +199.58% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.13 | +1,669.91% | 1 | May 14, 2024 |
Actinium Pharmaceuticals
Mar 31, 2026
Reiterates: Overweight
Price Target: $5
Current: $1.09
Upside: +358.72%
Immunome
Mar 4, 2026
Maintains: Overweight
Price Target: $33 → $30
Current: $21.48
Upside: +39.66%
Kymera Therapeutics
Mar 2, 2026
Maintains: Overweight
Price Target: $95 → $100
Current: $85.27
Upside: +17.27%
Apogee Therapeutics
Dec 17, 2025
Initiates: Overweight
Price Target: $95
Current: $84.01
Upside: +13.08%
Candel Therapeutics
Dec 8, 2025
Reiterates: Overweight
Price Target: $15
Current: $5.02
Upside: +198.80%
Pyxis Oncology
Nov 24, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $1.45
Upside: +451.72%
Arvinas
Nov 10, 2025
Maintains: Overweight
Price Target: $14 → $15
Current: $11.22
Upside: +33.69%
Delcath Systems
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $18
Current: $9.70
Upside: +85.57%
Centessa Pharmaceuticals
Oct 28, 2025
Initiates: Overweight
Price Target: $35
Current: $39.67
Upside: -11.77%
C4 Therapeutics
Sep 22, 2025
Reiterates: Overweight
Price Target: $6
Current: $2.84
Upside: +111.27%
Sep 9, 2025
Reiterates: Overweight
Price Target: $45
Current: $32.34
Upside: +39.15%
Jul 10, 2025
Reiterates: Overweight
Price Target: $30
Current: $15.79
Upside: +89.99%
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $43.98
Upside: +36.43%
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $24.98
Upside: +32.11%
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $3.67
Upside: +117.98%
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $4.89
Upside: +206.75%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $33.38
Upside: +199.58%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $1.13
Upside: +1,669.91%